New use of low-dose interleukin-2 (IL-2) in prevention and treatment of osteoporosis

Abstract

The invention belongs to the field of medicines, and in particular relates to a use of low-dose IL-2 for preparing a medicament for preventing and treating osteoporosis. The invention discloses a newmedical use of low-dose IL-2. The therapeutic medicine takes the low-dose IL-2 as a main active component, in a mouse disease model, after low-dose human recombinant IL-2 is administered, all indexesfor evaluating bone loss are significantly improved, the immunotherapy method obtains better practical therapeutic effects, and increases a safe and effective new medicine for clinically preventing and treating various types of osteoporosis, and further increases the new use to the clinical use of IL-2.

Description

technical field [0001] The invention belongs to the field of medicine, and relates to a new medical application of low-dose interleukin 2, in particular to the application of low-dose interleukin 2 in the preparation of medicines for preventing and treating osteoporosis. Background technique [0002] Osteoporosis (Osteoporosis) is a systemic bone disease that is prone to fractures due to the decrease in bone density and bone quality and the destruction of bone microstructure due to various reasons. It is the cause of menopausal women and the elderly. Osteoporotic osteoporosis is the most common, and its serious consequence is osteoporotic fractures. Due to living and eating habits and individual differences, the incidence of osteoporotic fractures in Asia has risen rapidly in recent years. About 1 / 3 of all fractures occur in Asia. According to the first comprehensive research report conducted by the International Osteoporosis Foundation on the bone health status of people i...

AI Technical Summary

Problems solved by technology

[0008] Domestic publication "Chinese Journal of Osteoporosis", Volume 5, Issue 3, August 1999, "The Role of Female Hormone and Interleukin-2 in the Pathogenesis of Type I Osteoporosis", Zhang Jie, Pei Zhuguo, Li Shuqin, also After women's natural menopause, the influence of changes in female hormones and interleukin-2 levels in the body on the onset of type Ⅰ osteoporosis and the relationship between them were reported. It is mentioned that IL-2 is an activated T -Lymphocyte product, there are few studies on the effect of IL-2 on bone mass, and there is no clear conclusion at present. Animal experiments have been proposed to show that IL-2 can stimulate bone resorption, but there is no disclosure of low-dose IL-2 Can inhibit the differentiation of monocytes into osteoclasts and bone resorption

In addition, "Journal of Radioimmunology", Volume 19, Issue 5, 2006, J of Radioimmunology2006, 19 (5), Sun Zihan, Luo Nanping, Niu Aijun, Qi Falian, etc., detected serum Leptin, IGF-Ⅰ, IL-2 in aged bone In the discussion on the application of patients with osteoporosis, it was proposed that in the development and change of human bone metabolism, the research on factors such as serum leptin, IGF-I, IL-2 should be strengthened, but it did not bring relevant technical inspiration to the present invention.

Images